Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...

TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 ...

The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and datopotamab deruxtecan (Dato-DXd), a TROP2 directed ADC, which are being jointly developed and commercialized globally ...

As someone who has firsthand experience scaling a company sustainably, I have witnessed the profound impact that the organizational structure can have on long-term success. Through my experiences ...

and Daiichi Sankyo is attempting to gain approval for its ADC patritumab deruxtecan. AstraZeneca, which also has a cancer drug partnership with Daiichi, markets Imfinzi and Tagrisso for several ...

Tanya Gupta, MD, evaluates fam-trastuzumab deruxtecan-nxki and its role in breast cancer treatment. Tanya Gupta, MD, medical oncologist in the Stanford University Department of Medicine, Division of ...

HSBC is simplifying its organizational structure into four businesses to streamline its businesses and reduce costs months after its new chief executive took over reins. Europe's largest bank by ...

Trastuzumab deruxtecan (T-DXd) continued to show benefit in the updated data from the DESTINY-Breast03 trial (NCT03529110). Special attention should be paid to the toxicities of nausea and pneumonitis ...